[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vistagen Therapeutics Inc (VTGN)

Vistagen Therapeutics Inc (VTGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,763
  • Shares Outstanding, K 44,377
  • Annual Sales, $ 1,270 K
  • Annual Income, $ -69,690 K
  • EBIT $ -72 M
  • EBITDA $ -72 M
  • 60-Month Beta 0.41
  • Price/Sales 9.92
  • Price/Cash Flow N/A
  • Price/Book 0.32
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.83
  • Most Recent Earnings $-0.37 on 06/15/26
  • Next Earnings Date 08/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 341.68% (-4.60%)
  • Historical Volatility 356.73%
  • IV Percentile 66%
  • IV Rank 43.53%
  • IV High 682.81% on 07/10/26
  • IV Low 78.68% on 08/12/25
  • Expected Move (DTE 11) 0.3145 (119.22%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 544
  • Volume Avg (30-Day) 229
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 29,392
  • Open Int (30-Day) 30,015
  • Expected Range 0.0000 to 0.5783

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.29
  • Number of Estimates 2
  • High Estimate $-0.23
  • Low Estimate $-0.35
  • Prior Year $-0.47
  • Growth Rate Est. (year over year) +38.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2170 +21.57%
on 07/27/26
0.3200 -17.56%
on 08/04/26
+0.0058 (+2.25%)
since 07/10/26
3-Month
0.1980 +33.23%
on 06/30/26
0.7997 -67.01%
on 06/29/26
-0.3467 (-56.79%)
since 05/08/26
52-Week
0.1980 +33.23%
on 06/30/26
5.1400 -94.87%
on 11/24/25
-2.7062 (-91.12%)
since 08/08/25

Most Recent Stories

More News
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose...

VTGN : 0.2638 (-8.28%)
SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics

SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies...

SRXH : 1.7300 (+8.81%)
VTGN : 0.2638 (-8.28%)
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder...

SRXH : 1.7300 (+8.81%)
VTGN : 0.2638 (-8.28%)
Vistagen Appoints Douglas J. Williamson to its Board of Directors

SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to...

VTGN : 0.2638 (-8.28%)
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Fasedienol did not achieve statistically significant improvement on primary and secondary endpoints In a post-hoc analysis, fasedienol achieved a nominal statistically...

VTGN : 0.2638 (-8.28%)
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month Completed...

VTGN : 0.2638 (-8.28%)
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product...

VTGN : 0.2638 (-8.28%)
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

NEW YORK , June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vistagen Therapeutics, Inc. (NASDAQ:...

VTGN : 0.2638 (-8.28%)
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

Vistagen , a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called...

VTGN : 0.2638 (-8.28%)
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

Dr. Angelov brings extensive industry experience across multiple therapeutic areas

VTGN : 0.2638 (-8.28%)

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

3rd Resistance Point 0.3292
2nd Resistance Point 0.3146
1st Resistance Point 0.2892
Last Price 0.2638
1st Support Level 0.2492
2nd Support Level 0.2346
3rd Support Level 0.2092

See More

52-Week High 5.1400
Fibonacci 61.8% 3.2522
Fibonacci 50% 2.6690
Fibonacci 38.2% 2.0858
Last Price 0.2638
52-Week Low 0.1980

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.